Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Change in Accured Expenses (2016 - 2026)

Spyre Therapeutics' Change in Accured Expenses history spans 11 years, with the latest figure at $3.1 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 78.99% year-over-year to $3.1 million; the TTM value through Dec 2025 reached -$764000.0, down 105.23%, while the annual FY2025 figure was -$764000.0, 105.23% down from the prior year.
  • Change in Accured Expenses reached $3.1 million in Q4 2025 per SYRE's latest filing, down from $4.4 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $14.9 million in Q4 2024 to a low of -$15.8 million in Q2 2024.
  • Average Change in Accured Expenses over 5 years is $386900.0, with a median of $452500.0 recorded in 2021.
  • The largest YoY upside for Change in Accured Expenses was 1768.46% in 2024 against a maximum downside of 849.0% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at $455000.0 in 2021, then decreased by 1.1% to $450000.0 in 2022, then tumbled by 298.0% to -$891000.0 in 2023, then skyrocketed by 1768.46% to $14.9 million in 2024, then crashed by 78.99% to $3.1 million in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Change in Accured Expenses are $3.1 million (Q4 2025), $4.4 million (Q3 2025), and -$2.3 million (Q2 2025).